Currently, ligand-mediated RNAi conjugates lead the market. However, future growth is anticipated in ligand-attached anti-sense therapies. In terms of targeting ligand types, peptides currently hold a ...

You may have heard of the consulting firm Gartner’s technology hype cycle—the technology trigger, the peak of inflated expectations, the trough of disillusionment, the slope of enlightenment, and the ...

Genentech's native HIC-MS method uses ammonium tartrate, enabling efficient MS detection without compromising chromatographic ...

The global cancer antibody drug conjugates market is experiencing significant expansion, with a projected increase from $8.19 billion in 2024 to $9.17 billion in 2025, reflecting ...

Global Cancer Antibody Drug Conjugates Market poised to exceed USD 70 billion by 2031, driven by over 20 approved drugs. Report offers insights into market size, sales, pricing, and clinical trials ...

The field of oncology has seen transformative advancements with the development of antibody-drug conjugates (ADCs), which are rapidly revolutionizing the treatment of several cancer types, including ...

The ADC market offers significant growth opportunities driven by the rising cancer incidence and demand for targeted ...

AJMC Insights Series features Kathleen Moore, MD, MS, a gynecologic oncologist and expert in ovarian cancer treatment. Dr Moore discusses various aspects of novel therapies for ovarian cancer ...

The conjugate space is evolving fast - moving beyond traditional ADCs into new formats like degrader-conjugates, oligonucleotide conjugates, bispecific ADCs, and more. The 4 th Novel Conjugates Summit ...

Please provide your email address to receive an email when new articles are posted on . Patients on ADCs with known ocular side effects require close ophthalmic monitoring. A cycle of topical ...

Trastuzumab deruxtecan in frontline maintenance Dr Moore discussed the challenge of prioritizing biomarkers when multiple are present: “I would always prioritize a ...